McN 5707
Mcn 5707 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.
Mcn 5707 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.
Mcn 5707 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.
Source: Wikipedia "McN 5707" · CC BY-SA 4.0
Share this article: X · Bluesky